West Pharmaceutical Services (WST) Cost of Revenue (2009 - 2026)

West Pharmaceutical Services (WST) has reported Cost of Revenue for 18 consecutive years, with $543.1 million the latest figure, recorded in Q2 2026.

• Quarterly Cost of Revenue rose 10.25% year-over-year to $543.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $2.1 billion (up 9.75% YoY) and the FY2025 annual result came in at $2.0 billion, up 3.98% from the prior year.
• Cost of Revenue eased to $543.1 million in Q2 2026 per WST's latest filing, from $548.5 million in the prior quarter.
• Over the last five years, Cost of Revenue for WST reached as high as $548.5 million in Q1 2026 and fell as low as $418.9 million in Q3 2022.
• A 5-year average of $473.8 million and a median of $465.6 million in 2024 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2022 — Cost of Revenue increased 0.14% — and 2026, when it advanced 17.68%.
• Year by year, Cost of Revenue stood at $446.6 million in 2022, then grew by 1.61% to $453.8 million in 2023, then gained by 4.72% to $475.2 million in 2024, then rose by 5.45% to $501.1 million in 2025, then gained by 8.38% to $543.1 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $543.1 million, $548.5 million, and $501.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.